MK-8189

DB19153InvestigationalSmall molecule

MK-8189 is under investigation in clinical trial NCT04624243 (Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)).

Mechanism: Pharmacologically active on cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Curator reviewed
Formula / weight: C₁₉H₂₂N₆OS · 382.49 g/mol (avg)
Also known as: 4-PYRIMIDINAMINE, 2-METHYL-6-(((1S,2S)-2-(5-METHYL-2-PYRIDINYL)CYCLOPROPYL)METHOXY)-N-((5-METHYL-1,3,4-THIADIAZOL-2-YL)METHYL)-
Code names: MK-8189

Resolves to

Compound

UNII7M430JI73BCAS1424371-93-6

Structure

InChIKeyWQKPZDLZRFTMTI-CABCVRRESA-NSMILESCC1=NN=C(CNC2=CC(OC[C@H]3C[C@@H]3C3=CC=C(C)C=N3)=NC(C)=N2)S1

Targets

Q9Y233PDE10A

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-8189, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account